All Genomics & Sequencing articles
-
NewsNew culture system yields billions of rare dendritic cells for preclinical research
A new 23-day bone marrow culture protocol produces over 1.5 billion conventional type 1 dendritic cells from a single mouse, offering researchers a consistent, high-purity supply of a cell type critical to tumour immunology and vaccine development.
-
InterviewHow multiomics can strengthen drug target discovery
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.
-
NewsImmune profiling could help tailor treatment for primary biliary cholangitis
A new review of primary biliary cholangitis reveals how interactions between bile duct epithelial cells and immune populations sustain chronic inflammation, and explores whether mapping individual disease mechanisms could guide more targeted therapies.
-
NewsHidden bacterial compounds reveal potential cancer drug leads
Researchers have discovered a new family of bacterial natural products that bind the cancer-associated enzyme AKR1C3, revealing potential starting points for drug discovery.
-
NewsPacBio and TychoBio partner to advance AI-driven RNA therapies
PacBio and AI drug discovery company TychoBio are generating full-length RNA datasets from more than 10,000 samples to train AI models and accelerate the development of RNA therapies for rare diseases.
-
NewsKRAS inhibition and CTLA-4 blockade could overcome gastric cancer immunotherapy resistance
Researchers have identified oncogenic KRAS as a key driver of immunosuppression in gastric adenocarcinoma.
-
NewsOestrogen receptor alpha identified as right ventricle protector in pulmonary hypertension
Scientists at National Jewish Health have identified oestrogen receptor alpha as a potential therapeutic target for preserving right ventricular function in pulmonary hypertension.
-
ArticleHow protective gene variants are revealing new drug targets
Finding the right drug target remains one of discovery’s biggest challenges. Human genetics is helping researchers strengthen the evidence before committing years of research and investment.
-
NewsMicroproteins emerge as potential new Alzheimer’s targets
Scientists at the Salk Institute have constructed a comprehensive atlas of previously uncharacterised microproteins in the human frontal cortex, identifying over 1,000 novel candidates.
-
ArticleSample collection: the overlooked key to genomic study success
As genomic studies become larger and more diverse, sample collection can make or break their success. Discover why collection strategy matters for recruitment, scale and data quality.
-
NewsWhole-genome sequencing delivers actionable biomarkers in 73 percent of cancer patients
A large real-world study demonstrates that whole-genome sequencing can identify actionable biomarkers in nearly three-quarters of solid cancer patients.
-
NewsOutSee secures £50k innovate UK grant for AI target validation
UK genomics and drug discovery company OutSee has received £50,000 in Innovate UK funding to develop an agentic AI sub-system designed to automate the initial triage of drug targets identified by its Nomaly genomics engine.
-
NewsNew malaria mutations linked to resistance against multiple front-line drugs
Whole-genome sequencing of parasites from Ugandan patients has uncovered a cluster of genetic variants linked to reduced susceptibility to multiple front-line malaria treatments, with researchers warning the mutations are spreading rapidly.
-
ArticleWhy depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
-
NewsPatient-derived tumour organoid biobank maps cancer gene dependencies
A biobank of 256 patient-derived tumour organoids, combined with genome-wide CRISPR–Cas9 screening, has produced a detailed map of cancer gene dependencies across five tumour types, revealing both shared vulnerabilities and mutation-specific targets with implications for precision oncology.
-
WebinarWhat it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
-
ReportBuilding biomarkers that drug developers can rely on
Discover how integrated technologies, multiomic approaches and AI are helping researchers translate complex biological signals into actionable tools for drug development and patient care.
-
ArticleHow rare genetic variants could uncover new drug targets
What if extreme levels of common traits have a different genetic basis? New research suggests rare, large-effect variants could help explain the extremes and identify potential drug targets.
-
Article600+ patient-derived cancer models expand the search for drug targets
Hundreds of new patient-derived cancer models could strengthen target validation, identify cancer vulnerabilities and provide more representative systems for preclinical drug discovery.
-
NewsAGR2 and FOXM1 identified as prognostic and therapeutic targets in NF-PanNETs
A new study using single-cell RNA sequencing has identified AGR2 as a potential prognostic marker and FOXM1 as a druggable target in non-functional pancreatic neuroendocrine tumours, offering new tools to stratify patients and guide treatment strategies.